The new anti-amyloid drugs for AD are interesting, but an efficacy of 3 points on a 144 scale (2%) does not sound so impressive. We also need to understand ARIA much more
Læs også
on 18. februar 2025 at 21:19
- Andreas Andersen
- 18. februar 2025
- 0
EU har planlagt nyt krisemøde onsdag mellem flere EU-lande, Norge og Canada. Herudover har EU planlagt en millitær støttepakke til Ukraine på 6 milliarder euro. […]
@Medicinmanden Det er en interessant pointe i artiklen, at konkurrencen mellem danske banker er for træg for tiden. Kan godt
- Andreas Andersen
- 26. maj 2021
- 0
@Medicinmanden Det er en interessant pointe i artiklen, at konkurrencen mellem danske banker er for træg for tiden. Kan godt forklare at samtlige banker indfører […]
@NielsANielsen @VibekeVind Og så skal samfundet stille en PCR test til rådighed for dig til det? Kan du ikke tage
- Andreas Andersen
- 18. december 2022
- 0
@NielsANielsen @VibekeVind Og så skal samfundet stille en PCR test til rådighed for dig til det? Kan du ikke tage en hjemmetest så eller alternativ […]
Agree that we need to characterize ARIA better and make sure doctors know how to predict it and manage it. On the efficacy, I struggle to see why such a change ( which is measurable and consistent on a clinical scale which is not so sensitive to begin with) should be meaningless.
If the clinical scale is so bad, then it might not be the best ending point to show efficacy of the drug, that can balance the side effects, expensive price and changes in diagnostic setup of AD. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients and relatives.